{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T23:47:58Z","timestamp":1783381678121,"version":"3.54.6"},"reference-count":17,"publisher":"Georg Thieme Verlag KG","issue":"09","license":[{"start":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T00:00:00Z","timestamp":1736985600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Thromb Haemost"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The benefits and risks of extending anticoagulant treatment beyond the first 3 to 6 months in patients with venous thromboembolism (VTE) in clinical practice are not well understood.<\/jats:p><jats:p>ETNA-VTE Europe is a prospective, noninterventional, post-authorization study in unselected patients with VTE treated with edoxaban in eight European countries for up to 18 months. Recurrent VTE, major bleeding, and all-cause death were the primary study outcomes.<\/jats:p><jats:p>The median age of the 2,644 patients was 65 years; 46.6% were female, and 22.8% had a history of VTE. The median treatment duration was 50.6 weeks (interquartile range: 23.4\u201377.7). VTE recurrence occurred in 100 patients (3.8% at an annual rate of 2.7%\/year); 37 patients (1.4%) were on edoxaban at the time of the event, with a corresponding annualized rate of 1.6%\/year. Major bleeding was experienced by 37 patients (1.4%) during edoxaban treatment, corresponding to an annualized rate of 1.5%\/year. Overall, 95 patients died (3.6%; annualized rate 2.6%\/year), with the majority for reasons other than VTE- and cardiovascular (CV)-related causes. Out of 15 deaths (1.9%; annualized rate 2.1%\/year) that occurred during edoxaban treatment, 1 was related to VTE and 11 related to CV (annualized rate 0.0%\/year and 0.5%\/year).<\/jats:p><jats:p>ETNA-VTE Europe provides evidence for the real-world effectiveness of edoxaban treatment (up to 18 months) based on a low rate of VTE recurrence, all-cause death, and major bleeding, and is aligned with the results of the randomized clinical trial reassuring the use of edoxaban in the treatment of VTE in routine clinical practice.<\/jats:p>","DOI":"10.1055\/a-2497-4089","type":"journal-article","created":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T18:51:28Z","timestamp":1737053488000},"page":"880-892","source":"Crossref","is-referenced-by-count":4,"title":["Treatment of Venous Thromboembolism with Edoxaban over 18 Months: Results from ETNA-VTE Europe"],"prefix":"10.1055","volume":"125","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4308-7797","authenticated-orcid":false,"given":"Giancarlo","family":"Agnelli","sequence":"additional","affiliation":[{"name":"Internal Emergency and Vascular Medicine-Stroke Unit, University of Perugia, Perugia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Hoffmann","sequence":"additional","affiliation":[{"name":"Division of Angiology, Medical Clinic IV, Ludwig-Maximilians-University, University Hospital, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Hainaut","sequence":"additional","affiliation":[{"name":"Department of General Internal Medicine, Cliniques Universitaires Saint Luc, UCL, Bruxelles, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Gaine","sequence":"additional","affiliation":[{"name":"National Pulmonary Hypertension Unit, Mater Misericordiae University Hospital, Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cihan","family":"Ay","sequence":"additional","affiliation":[{"name":"Clinical Division of Haematology and Haemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiel","family":"Coppens","sequence":"additional","affiliation":[{"name":"Vascular Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands"},{"name":"Amsterdam Cardiovascular Sciences, Pulmonary Hypertension and Thrombosis, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Schindewolf","sequence":"additional","affiliation":[{"name":"Division of Angiology, Swiss Cardiovascular Center, University of Bern, Inselspital, Bern University Hospital, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4571-7721","authenticated-orcid":false,"given":"David","family":"Jimenez","sequence":"additional","affiliation":[{"name":"Respiratory Department, Ram\u00f3n y Cajal Hospital, Madrid, Spain"},{"name":"Medicine Department, Universidad de Alcala, Madrid, Spain"},{"name":"CIBER Enfermedades Respiratorias (CIBERES), Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva-Maria","family":"Fronk","sequence":"additional","affiliation":[{"name":"Daiichi Sankyo Europe GmbH, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Souza","sequence":"additional","affiliation":[{"name":"Daiichi Sankyo Europe GmbH, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Laeis","sequence":"additional","affiliation":[{"name":"Daiichi Sankyo Europe GmbH, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4970-2110","authenticated-orcid":false,"given":"Peter","family":"Bramlage","sequence":"additional","affiliation":[{"name":"Institute for Pharmacology and Preventive Medicine, Cloppenburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Br\u00fcggenj\u00fcrgen","sequence":"additional","affiliation":[{"name":"Orthopedic Department, Medical School Hannover (MHH) at DIAKOVERE Annastift, Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Levy","sequence":"additional","affiliation":[{"name":"LEDa-LEGOS, Universit\u00e9 Paris\u2013Dauphine, PSL University, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander T.","family":"Cohen","sequence":"additional","affiliation":[{"name":"Guy's and St Thomas' NHS Foundation Trust, King's College London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the ETNA-VTE-Europe investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2025,1,16]]},"reference":[{"issue":"11","key":"ref1","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1161\/ATVBAHA.114.304488","article-title":"Thrombosis: a major contributor to global disease burden","volume":"34","author":"G E Raskob","year":"2014","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"04","key":"ref2","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1093\/eurheartj\/ehz236","article-title":"Trends in thrombolytic treatment and outcomes of acute pulmonary embolism in Germany","volume":"41","author":"K Keller","year":"2020","journal-title":"Eur Heart J"},{"issue":"09","key":"ref3","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1161\/CIRCRESAHA.115.306841","article-title":"Global burden of thrombosis: epidemiologic aspects","volume":"118","author":"A M Wendelboe","year":"2016","journal-title":"Circ Res"},{"issue":"15","key":"ref4","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1056\/NEJMoa1306638","article-title":"Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism","volume":"369","author":"H R B\u00fcller","year":"2013","journal-title":"N Engl J Med"},{"issue":"04","key":"ref5","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/eurheartj\/ehz405","article-title":"2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)","volume":"41","author":"S V Konstantinides","year":"2020","journal-title":"Eur Heart J"},{"issue":"47","key":"ref6","doi-asserted-by":"crossref","first-page":"4208","DOI":"10.1093\/eurheartj\/ehx003","article-title":"Diagnosis and management of acute deep vein thrombosis: a joint consensus document from the European Society of Cardiology working groups of aorta and peripheral vascular diseases and pulmonary circulation and right ventricular function","volume":"39","author":"L Mazzolai","year":"2018","journal-title":"Eur Heart J"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.thromres.2020.09.001","article-title":"ETNA-VTE Europe: benefits and risks of venous thromboembolism treatment using edoxaban in the first 3 months","volume":"196","author":"G Agnelli","year":"2020","journal-title":"Thromb Res"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12959-018-0163-7","article-title":"Design and rationale of the non-interventional, edoxaban treatment in routiNe clinical prActice in patients with venous ThromboEmbolism in Europe (ETNA-VTE-Europe) study","volume":"16","author":"A T Cohen","year":"2018","journal-title":"Thromb J"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ejim.2020.08.014","article-title":"ETNA VTE Europe: a contemporary snapshot of patients treated with edoxaban in clinical practice across eight European countries","volume":"82","author":"A T Cohen","year":"2020","journal-title":"Eur J Intern Med"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1477-9560-12-21","article-title":"Venous thromboembolism in the elderly: efficacy and safety of non-VKA oral anticoagulants","volume":"12","author":"V Geldhof","year":"2014","journal-title":"Thromb J"},{"issue":"03","key":"ref11","doi-asserted-by":"crossref","first-page":"e245","DOI":"10.1055\/s-0040-1716496","article-title":"Impact of patient characteristics on treatment outcomes in symptomatic venous thromboembolism: results of HOKUSAI-VTE randomized trial analysis","volume":"4","author":"B van Hout","year":"2020","journal-title":"TH Open"},{"issue":"07","key":"ref12","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1161\/CIRCULATIONAHA.113.004450","article-title":"Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis","volume":"129","author":"S Schulman","year":"2014","journal-title":"Circulation"},{"issue":"26","key":"ref13","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"Oral rivaroxaban for symptomatic venous thromboembolism","volume":"363","author":"R Bauersachs","year":"2010","journal-title":"N Engl J Med"},{"issue":"12","key":"ref14","first-page":"CD011088","article-title":"Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in patients with unprovoked venous thromboembolism","volume":"12","author":"L Robertson","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"02","key":"ref15","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","article-title":"Antithrombotic therapy for VTE disease: CHEST Guideline and Expert Panel Report","volume":"149","author":"C Kearon","year":"2016","journal-title":"Chest"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1076029620945792","DOI":"10.1177\/1076029620945792","article-title":"Treatment decision-making of secondary prevention after venous thromboembolism: data from the real-life START2-POST-VTE register","volume":"26","author":"E Antonucci","year":"2020","journal-title":"Clin Appl Thromb Hemost"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1753466619878556","DOI":"10.1177\/1753466619878556","article-title":"Extended anticoagulation after venous thromboembolism: should it be done?","volume":"13","author":"C J Fernandes","year":"2019","journal-title":"Ther Adv Respir Dis"}],"container-title":["Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2497-4089.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T22:36:58Z","timestamp":1755902218000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2497-4089"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,16]]},"references-count":17,"journal-issue":{"issue":"09","published-online":{"date-parts":[[2025,8,22]]},"published-print":{"date-parts":[[2025,9]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2497-4089","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0340-6245","2567-689X"],"issn-type":[{"value":"0340-6245","type":"print"},{"value":"2567-689X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,16]]}}}